Chemical inhibitors of βENaC are compounds that affect the epithelial sodium channel at the level of the beta subunit, resulting in the reduction of the channel's sodium reabsorption capability. These inhibitors function by directly binding to the sodium pore, altering the electrochemical gradients, modulating the trafficking and membrane expression, or affecting the regulatory mechanisms of the channel. The inhibitors like amiloride and its analogs, including benzamil, phenamil, and HMA, function by occluding the sodium pore of βENaC, preventing sodium ions from entering the epithelial cells, and thus reducing the activity of the channel. In contrast, compounds such as methazolamide and EIPA work by inducing intracellular pH changes, which indirectly affect the channel's trafficking to the membrane and its stability, without directly blocking the sodium-conducting pore. Other compounds, such as glibenclamide and hydrochlorothiazide, do not target βENaC directly but instead influence the activity by modifying the electrochemical gradients across epithelial tissues where βENaC is a critical component for sodium reabsorption.
Moreover, spironolactone, by antagonizing aldosterone receptors, leads to a downstream effect that decreases the expression and activity of ENaC channels, including βENaC. In addition, probenecid affects the function of βENaC by altering cellular metabolites, thereby impacting its expression and regulatory mechanisms. Lastly, bumetanide, by inhibiting NKCC2, also indirectly influences βENaC activity due to its role in the ionic gradients that drive sodium reabsorption. These inhibitors, through various biochemical and cellular pathways, contribute to the modulation of βENaC function, highlighting the diverse mechanisms by which the activity of this channel can be regulated. The actions of these inhibitors underline the complexity of βENaC regulation, involving multiple layers of control ranging from direct pore blockage to indirect effects on regulatory pathways and cellular processes that govern the channel's function.
SEE ALSO...
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Amiloride | 2609-46-3 | sc-337527 | 1 g | $290.00 | 7 | |
Amiloride directly binds to and blocks ENaC channels, including βENaC, by occluding the sodium pore, preventing sodium reabsorption which characterizes its inhibition mechanism. | ||||||
Triamterene | 396-01-0 | sc-213103A sc-213103 | 1 g 5 g | $22.00 $53.00 | ||
Triamterene acts as a potassium-sparing diuretic, it blocks ENaC channels including the β subunit, reducing sodium reabsorption in kidney tubules and thus its activity. | ||||||
Methazolamide | 554-57-4 | sc-235615 | 1 g | $92.00 | 3 | |
Methazolamide, a carbonic anhydrase inhibitor, leads to intracellular acidosis which can modulate the trafficking and surface expression of βENaC, indirectly reducing its activity. | ||||||
5-(N-Ethyl-N-isopropyl)-Amiloride | 1154-25-2 | sc-202458 | 5 mg | $102.00 | 20 | |
EIPA is an amiloride derivative that blocks Na+/H+ exchange, leading to intracellular pH changes that may influence βENaC channel trafficking and membrane stability. | ||||||
Glyburide (Glibenclamide) | 10238-21-8 | sc-200982 sc-200982A sc-200982D sc-200982B sc-200982C | 1 g 5 g 25 g 100 g 500 g | $45.00 $60.00 $115.00 $170.00 $520.00 | 36 | |
Glibenclamide, an ATP-sensitive potassium channel blocker, indirectly modulates ENaC activity, including βENaC, by altering cellular excitability and electrochemical gradients. | ||||||
Hydrochlorothiazide | 58-93-5 | sc-207738 sc-207738A sc-207738B sc-207738C sc-207738D | 5 g 25 g 50 g 100 g 250 g | $54.00 $235.00 $326.00 $551.00 $969.00 | ||
Hydrochlorothiazide, a thiazide diuretic, indirectly influences βENaC activity by modulating the electrochemical gradient and sodium reabsorption dynamics in the distal convoluted tubule. | ||||||
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $107.00 | 3 | |
Spironolactone antagonizes aldosterone receptors, leading to decreased expression and activity of ENaC channels including βENaC in the renal collecting duct. | ||||||
Probenecid | 57-66-9 | sc-202773 sc-202773A sc-202773B sc-202773C | 1 g 5 g 25 g 100 g | $27.00 $38.00 $98.00 $272.00 | 28 | |
Probenecid inhibits organic anion transporters and can alter cellular metabolite levels, which in turn may affect βENaC expression and function through metabolic regulation. | ||||||
Bumetanide (Ro 10-6338) | 28395-03-1 | sc-200727 sc-200727A | 1 g 5 g | $107.00 $224.00 | 9 | |
Bumetanide, a loop diuretic that inhibits NKCC2, leads to alterations in ionic gradients, affecting the driving force for sodium reabsorption where βENaC is involved. |